Management of granulosa cell tumour of the ovary

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 560-564

  Jamieson, Stacey ^a   Fuller, Peter J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Granulosa cell tumours; Hormones; Ovarian neoplasms; Therapeutics; Tumour markers

Indexed keywords

ANASTROZOLE; BUSERELIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FOLLITROPIN RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FORMESTANE; G PROTEIN COUPLED RECEPTOR; GROWTH DIFFERENTIATION FACTOR 9; IMATINIB; INHIBIN; INHIBIN A; INHIBIN B; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MUELLERIAN INHIBITING FACTOR; NILOTINIB; PLATINUM DERIVATIVE; PROTEIN FOXL2; STEROIDOGENIC FACTOR 1; TAMOXIFEN; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CARCINOGENESIS; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; EARLY CANCER; GRANULOSA CELL TUMOR; GSP ONCOGENE; HUMAN; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVARIECTOMY; OVARY CANCER; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; FEMALE; OVARY TUMOR;

FEMALE; GRANULOSA CELL TUMOR; HUMANS; OVARIAN NEOPLASMS;

EID: 59649086035     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328306316f     Document Type: Review

References (51)

1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180-1189.
2. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J Clin Oncol 2007; 25:2944-2951.
3. Fuller PJ, Chu S, Fikret S, Burger HG. Molecular pathogenesis of granulosa cell tumours. Mol Cell Endocrinol 2002; 191:89-96.
4. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary: an analysis of 376 women. Gynecol Oncol 2007; 104:396-400.
5. Amsterdam A, Selvaraj N. Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. Endocr Rev 1997; 18:435-461.
6. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 2004; 15:122-128.
7. Anttonen M, Unkila-Kallio L, Leminen A, et al. High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab 2005; 90:6529-6535.
8. Chu S, Rushdi S, Zumpe ET, et al. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod 2002; 8:426-433.
9. Dumont JE, Jauniaux JC, Roger PP. The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci 1989; 14:67-71.
10. Vallar L Oncogenic role of heterotrimeric G proteins. Cancer Surv 1996; 27: 325-338.
11. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340:692-696.
12. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249:655-659.
13. Fragoso MC, Latronico AC, Carvalho FM, et al. Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 1998; 83:2074-2078.
14. Ligtenberg MJ, Siers M, Themmen AP, et al. Analysis of mutations in genes of the follicle-stimulating hormone receptor signaling pathway in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1999; 84:2233-2234.
15. salpha activating mutations. J Pediatr Endocrinol 2002; 15 (Suppl 3):891-895.
16. Calaminus G, Wessalowski R, Harms D, Gobel U. Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecol Oncol 1997; 65: 447-452.
17. Kalfa N, Ecochard A, Patte C, et al. Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? J Clin Endocrinol Metab 2006; 91:1842-1847.
18. Kalfa N, Philibert P, Patte C, et al. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil Steril 2007; 87:896-901. This article, together with the previous one from the same group [17], provides very interesting insights into the pathogeneisis of juvenile GCT.
19. Tuteja G, Kaestner KH. Forkhead transcription factors II. Cell 2007; 131:192.
20. Uhlenhaut NH, Treier M. Fox12 function in ovarian development. Mol Genet Metab 2006; 88:225-234.
21. Fuller PJ, Zumpe ET, Chu S, et al. Inhibin-activin receptor subunit gene expression in ovarian tumors. J Clin Endocrinol Metab 2002; 87:1395-1401.
22. Roberts VJ, Barth S, el-Roeiy A, Yen SS. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab 1993; 77:1402-1410.
23. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999; 84:4025-4030.
24. Lappohn RE, Burger HG, Bouma J, et al. Inhibin as a marker for granulosa-cell tumors. N Engl JMed 1989; 321:790-793.
25. McLachlan Rl, Robertson DM, Burger HG, de Kretser DM. The radioimmu-noassay of bovine and human follicular fluid and serum inhibin. Mol Cell Endocrinol 1986; 46:175-185.
26. Burger HG, Robertson DM, Cahir N, et al. Characterization of inhibin immunoreactivity in postmenopausal women with ovarian tumours. Clin Endocrinol (Oxf) 1996; 44:413-418.
27. Robertson DM, Cahir N, Burger HG, et al. Inhibin forms in serum from postmenopausal women with ovarian cancers. Clin Endocrinol (Oxf) 1999; 50: 381-386.
28. Petraglia F, Luisi S, Pautier P, et al. Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab 1998; 83: 1029-1032.
29. Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer. Cancer Lett 2007; 249:14-17. This recent study from the group that originally isolated inhibin provides a very useful overview of the current role of inhibin assays in GCT diagnosis and management.
30. Robertson DM, Cahir N, Findlay JK, et al. The biological and immunological characterization of inhibin A and B forms in human follicular fluid and plasma. J Clin Endocrinol Metab 1997; 82:889-896.
31. Robertson DM, Stephenson T, Pruysers E, et al. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 2002; 191:97-103.
32. Mom CH, Engelen MJA, Willemse PHB, et al. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 2007; 105:365-372. A large study confirming previous findings which demonstrates the value of serum inhibin measurement in the follow-up of GCT.
33. Robertson DM, Cahir N, Burger HG, et al. Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin Chem 1999; 45:651-658.
34. Robertson DM, Stephenson T, Cahir N, et al. Development of an inhibin alpha subunit ELISA with broad specificity. Mol Cell Endocrinol 2001; 180:79-86.
35. Robertson DM, Stephenson T, Pruysers E, et al. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer. J Clin Endocrinol Metab 2002; 87:816-824.
36. Gustafson ML, Lee MM, Scully RE, et al. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992; 326:466-471.
37. Lane AH, Lee MM, Fuller AF Jr, et al. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999; 73:51-55.
38. Long WQ, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000; 85:540-544.
39. Rey RA, Lhomme C, Marcillac I, et al. Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 1996; 174:958-965.
40. La Marca A, Volpe A. The anti-Müllerian hormone and ovarian cancer. Hum Reprod Update 2007; 13:265-273. A useful overview of the potential use of anti-Müllerian hormone in the management of ovarian cancer.
41. Freeman SA, Modesitt S C. Anastrozole therapy in recurrent ovarian adult granulosa cell tu mors: a report of 2 cases. Gynecol Oncol 2006; 103:755-758.
42. Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 2005; 96:865-869.
43. Savage P, Constenla D, Fisher C, et al. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol) 1998; 10:242-245.
44. Maxwell GL, Soisson AP, Miles P. Failure of gonadotropin releasing hormone therapy in patients with metastatic ovarian sex cord stromal tumors. Oncology 1994; 51:356-359.
45. Chu S, Mamers P, Burger HG, Fuller PJ. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab 2000; 85:1200-1205.
46. Chu S, Nishi Y, Yanase T, et al. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol Endocrinol 2004; 18:1919-1928.
47. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor β: an overview and update. Nucl Receptor Signaling 2008; 6: e003.
48. Jakob A, Geiger R, Freidrich WH. Successful treatment of a patient with a granulosa/theca cell tumor of the ovary with STI571 (Gleevic) [Abstract 1904]. Proc Am Soc Clin Oncol 2002; 21:24b.
49. Chu S, Alexiadis M, Fuller PJ. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol 2008; 108:182-190. This study from our own group raises the possibility that targeted therapy with an appropriate TKI may have a role in the treatment of GCTs.
50. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502.
51. Keshava N, Gubba S, Tekmal RR. Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis. J Soc Gynecol Investig 1999; 6:41-49.